Status:
UNKNOWN
Integrative Management of Patients With Atrial Fibrillation Via Hospital-Community-Family-Based Telemedicine (HCFT-AF) Program
Lead Sponsor:
Northern Jiangsu People's Hospital
Conditions:
Telemedicine
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Atrial fibrillation (AF) is one of the most common arrhythmias. Its repeated fluctuations in ventricular rate and irregular heart rhythm not only reduce exercise tolerance and quality of life, but als...
Detailed Description
Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up. In the program, participants were educated on the use of smart health-tracking devices and ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old;
- Meeting the diagnostic criteria for atrial fibrillation;
- Subjects can understand the situation of this study and agree to sign informed consent and continue to follow up.
Exclusion
- Atrial fibrillation caused by reversible causes, including: acute myocardial infarction (MI) within 1 month, acute myocarditis within 1 month, untreated hyperthyroidism, and electrophysiological examination, angiography, atrial fibrillation did not reappear after treatment;
- There is no recurrence of atrial fibrillation after surgical treatment;
- Due to other serious diseases, the expected survival time is less than 1 year;
- Severe liver and kidney disease: serum creatinine\>5.0mg/dl; ALT exceeds the reference value by more than 3 times (ALT\> 100u/L);
- Systolic or diastolic blood pressure ≥ 180/110mm Hg (1mm Hg = 0.133kPa), but can be selected after blood pressure control;
- Diagnosed or suspected blood system diseases (except for mild to moderate anemia) leading to coagulopathy or accompanied by bleeding tendency;
- Pregnant and lactating women;
- Reluctance to use remote monitoring equipment (such as depression, dementia, impaired autonomy, lack of communication skills);
- Participating in other treatment research or remote patient management programs;
- The investigator consider that it is not suitable for joining the study;
Key Trial Info
Start Date :
November 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2023
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04127799
Start Date
November 1 2019
End Date
September 30 2023
Last Update
June 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of cardiovascular medicine,Northern Jiangsu Hospital
Yangzhou, Jiangsu, China, 225001